Evaluating outcomes of ALK-positive lung cancer patients treated with Alectinib after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the clinical outcomes and characteristics of adult patients with resected stage II-IIIB ALK-positive non-small-cell lung cancer (NSCLC) who receive Alectinib as adjuvant therapy. Conducted across multiple centers in China, the study will track patients who have undergone complete surgical resection and started Alectinib treatment within 28 days post-surgery. The focus is on understanding the effectiveness and safety of Alectinib in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically-confirmed stage II-IIIA or selected IIIB (T3N2) NSCLC as per the American Joint Committee on Cancer and International Union Against Cancer (UICC/AJCC), 8th edition
* ALK positive
* Postoperative NSCLC patients who have undergone complete resection
* Had taken Alectinib monotherapy without prior systemic therapy (including other ALK-TKIs or chemotherapy) as adjuvant† therapy for resected stage II-IIIB ALKpositive NSCLC and the time from the first dose to enrollment was no more than 28 days

Exclusion Criteria:

* Patients participating in interventional study of adjuvant treatment
* Pregnant, lactating, or breastfeeding women

Where it's running

• Affiliated Hospital of Guangdong Medical University
  Zhanjiang, Guangdong, China Recruiting
• Affiliated Cancer Hospital and Institute of Guangzhou Medical University
  Guangzhou, Guangzhou, China Recruiting
• Huai He Hospital of Henan University
  Kaifeng, Henan, China Recruiting
• Henan Provincial Chest Hospital
  Zhengzhou, Henan, China Recruiting
• The First Affiliated Hospital of Xinjiang Medical University
  Ürümqi, Xinjiang, China Recruiting
• Peking University First Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Reference Study ID Number: ML45766 https://forpatients.roche.com/ No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. and Canada)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing standard and adjusted doses of alectinib for lung cancer treatment

  This study is testing if adjusting the dose of alectinib based on blood levels can help people with ALK positive lung cancer live longer without their disease getting worse compared to the standard dose.

  Recruiting at 7 sites Phase 4 University Medical Center Groningen · Villejuif, Val-de-Marne and 7 other locations · NCT05525338

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Intratumoral injection of N17350 in advanced solid tumors

  Aims to see if injected N17350 can shrink or control tumors in adults with advanced solid cancers who have few other options.

  Recruiting at 7 sites Phase 1/2 Onchilles Pharma Inc · Los Angeles, California and 8 other locations · NCT07339176

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.